Carfilzomib
Catalog Number : 8681740
description
Carfilzomib is a selective irreversible proteasome inhibitor and analog of epoxomicin. It binds to and inhibits the chymotrypsin-like activity of the 20S proteasome. Carfilzomib is reported to inhibit tumor growth and induce cell cycle arrest and apoptosis.
Additional Information
Applications: | FA |
Synonyms: | Kyprolis, PR-171 |
Formulation: | Crystalline solid |
Chemical Name: | (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide |
Molecular Formula: | C40H57N5O7 |
Molecular Weight: | 719.9 |
CAS Number | 868540-17-4 |
Purity: | 98% |
Storage Conditions: | Product should be kept at -20°C. |
References: | Kortuem, K. M., & Stewart, A. K. (2013). Carfilzomib. Blood, The Journal of the American Society of Hematology, 121(6), 893-897.
Yang, J., Wang, Z., Fang, Y., Jiang, J., Zhao, F., Wong, H., ... & Kirk, C. J. (2011). Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metabolism and Disposition, 39(10), 1873-1882.
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., ... & Goranova-Marinova, V. (2015). Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 372(2), 142-152. |